Streetbeat News

Stock Prices

ASPN

BMY

EXPE

FUSN

GLP

MELI

META

MIST

ORGO

PINS

Wall Street analysts have updated their price targets and ratings for several companies. Fusion Pharmaceuticals' target was raised by Raymond James, who also upgraded the stock to Strong Buy. Organogenesis and Aspen Aerogels had their targets raised by BTIG and Canaccord Genuity, respectively, both maintaining Buy ratings. Pinterest's target was increased by Wedbush, but the rating remained Neutral. Expedia's target was raised by BTIG with a Buy rating. Bristol-Myers Squibb's target was cut by B of A Securities, yet the rating stayed at Buy. Meta Platforms' target was significantly raised by Wedbush, maintaining an Outperform rating. Milestone Pharmaceuticals had its target cut by TD Cowen, but kept an Outperform rating. Global Partners' target was raised by Stifel with a Buy rating. MercadoLibre also saw a target increase by Wedbush, maintaining an Outperform rating.

Portfolio Pulse from Avi Kapoor

December 27, 2023 | 2:06 pm

MTNB

Matinas Biopharma's stock is up following the announcement of positive results from in vivo studies showing successful oral delivery of LNC-formulated oligonucleotides.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 2:06 pm

BKNG

Wedbush analyst Scott Devitt has maintained an Outperform rating on Booking Holdings (NASDAQ:BKNG) and increased the price target from $3300 to $3850, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 2:05 pm

LRHC

La Rosa Holdings Corp. (NASDAQ: LRHC) has acquired a 51% interest in its franchisee, La Rosa Realty Orlando, LLC, which generated $3.6 million in revenue and positive net income in 2022. Despite a down market, Realty Orlando increased transactions by 14% in 2023 compared to 2022. The company aims for a $100 million annual revenue run rate by end of 2024 and plans to acquire more franchisees soon.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 2:02 pm

Micron Technology (NASDAQ:MU) has delivered an average annual return of 21.74% over the past 5 years, outperforming the market by 8.01% on an annualized basis. A $1000 investment in MU 5 years ago would be worth $2,759.85 today. Micron Technology currently has a market cap of $96.67 billion.

Portfolio Pulse from Benzinga Insights

December 27, 2023 | 2:01 pm

PINS

Analysts have provided mixed evaluations of Pinterest (NYSE:PINS) with 17 ratings over the past three months. The average 12-month price target is $36.18, up 13.88% from the previous target. Recent analyst actions mostly involve raising price targets and ratings, reflecting a positive outlook on Pinterest's performance. The company's financials show strong revenue growth and net margin but below-average ROE and ROA. Pinterest's market cap is below industry averages, and it has a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 27, 2023 | 2:00 pm

PWR

Quanta Services Inc. (NYSE:PWR) stock is currently at $214.17, down 0.23% in the current session, but up 15.65% over the past month and 50.51% over the past year. The company's P/E ratio of 45.77 is lower than the Construction & Engineering industry average of 48.69, which could suggest undervaluation or weaker growth prospects.

Portfolio Pulse from Benzinga Insights

December 27, 2023 | 2:00 pm

LIDRW

Trading for LIDRW was halted and then resumed at 9:00 AM ET, with updated quotation resumption times provided.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 2:00 pm

OTLK

Capital One analyst Zegbeh Jallah has upgraded Outlook Therapeutics (NASDAQ:OTLK) from Equal-Weight to Overweight and set a price target of $5. This upgrade reflects a positive view on the company's prospects.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:58 pm

CATX

GOVX

VRME

Insiders at Perspective Therapeutics, VerifyMe, and GeoVax Labs have recently made notable stock purchases. Perspective Therapeutics Director Robert F. Williamson III bought shares following the divestiture of its brachytherapy business. VerifyMe's CEO Adam Stedham purchased shares after the board approved a share repurchase program. GeoVax Labs' CMO Kelly McKee acquired shares as the company expanded rights under an NIH license for COVID-19, Mpox, and smallpox.

Portfolio Pulse from Avi Kapoor

December 27, 2023 | 1:55 pm